Tetrahydrocannabivarin-9 - GW Pharmaceuticals

Drug Profile

Tetrahydrocannabivarin-9 - GW Pharmaceuticals

Alternative Names: Delta-9-tetrahydrocannabivarin; GW-42004; GWP-42004; Tetrahydrocannabivarol; THCV

Latest Information Update: 26 Sep 2016

Price : $50

At a glance

  • Originator GW Pharmaceuticals
  • Class Antihyperglycaemics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor CB1 antagonists; Cannabinoid receptor CB2 antagonists; Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 06 Aug 2015 Phase II development is ongoing in United Kingdom
  • 01 Mar 2014 GW Pharmaceuticals initiates enrolment in a phase IIb trial for Type-2 diabetes mellitus in United Kingdom (EudraCT2013-001140-61)
  • 01 Feb 2014 Phase-II clinical trials in Type-2 diabetes mellitus in Romania (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top